Conference Coverage

Obesity may attenuate anti-TNF response in psoriatic arthritis


 

References

DANBIO is supported by unrestricted grants from Abbott, Pfizer, MSD, Bristol-Myers Squibb, Roche, and UCB-Nordic. The sponsors have had no influence on data collection, analysis, or publication. ICEBIO is part of the electronic medical record system held by the University of Reykjavik and receives no industrial funding. Ms. Højgaard has received speaking fees from Celgene and UCB not related to this work.

Pages

Recommended Reading

Fresh evidence of methotrexate efficacy in psoriatic arthritis
MDedge Internal Medicine
Ixekizumab approved for plaque psoriasis
MDedge Internal Medicine
Severe psoriasis, kidney disease linked
MDedge Internal Medicine
Inflectra becomes first FDA-approved biosimilar for inflammatory diseases
MDedge Internal Medicine
Clazakizumab safe, effective for PsA treatment
MDedge Internal Medicine
Psoriasis tied to abdominal aortic aneurysm in nationwide study
MDedge Internal Medicine
Effective psoriasis therapy may reduce coronary plaque burden
MDedge Internal Medicine
Remicade to infliximab biosimilar switches fare well in real-life practice
MDedge Internal Medicine
Serious infections are increasing among psoriasis inpatients
MDedge Internal Medicine
Full resolution of psoriasis in half of ixekizumab patients
MDedge Internal Medicine